In a research report entitled, “Why HCV Sales Could Miss Consensus”, Morgan Stanley analyst Matthew Harrison today reiterated an Equal-weight rating on shares of Gilead Sciences (NASDAQ:GILD), …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target of $127.00, …
In a report sent to investors Tuesday, William Blair analyst John Sonnier reiterated an Outperform rating on Gilead Sciences (NASDAQ:GILD), following last week’s news that the FDA …
Gilead Sciences (NASDAQ: GILD) is a Foster City, California based bio-pharmaceutical company that discovers, develops and commercializes therapeutics for unmet medical areas in need. …
In a research note published today, Deutsche Bank analyst Robyn Karnauskas reaffirmed a Buy rating on Gilead Sciences (NASDAQ:GILD) with a $142 price target, …
In a research note released today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Gilead Sciences (NADAQ:GILD) with a $142 price …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a $127 price …
In a research report released Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Gilead Sciences (GILD) with a price target …
